Fennec Pharmaceuticals Inc. (TSX:FRX)

Canada flag Canada · Delayed Price · Currency is CAD
11.33
0.00 (0.00%)
Jun 4, 2025, 9:30 AM EDT
25.89%
Market Cap 297.81M
Revenue (ttm) 44.43M
Net Income (ttm) -20.75M
Shares Out n/a
EPS (ttm) -0.76
PE Ratio n/a
Forward PE 30.69
Dividend n/a
Ex-Dividend Date n/a
Volume 136
Average Volume 585
Open 11.33
Previous Close 11.33
Day's Range 11.33 - 11.33
52-Week Range 5.65 - 11.68
Beta 0.40
RSI 69.27
Earnings Date May 12, 2025

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1996
Employees 32
Stock Exchange Toronto Stock Exchange
Ticker Symbol FRX
Full Company Profile

Financial Performance

In 2024, Fennec Pharmaceuticals's revenue was $47.54 million, an increase of 123.69% compared to the previous year's $21.25 million. Losses were -$436,000, -97.28% less than in 2023.

Financial numbers in USD Financial Statements

News

Fennec Announces Results of Annual Meeting

RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy cir...

2 days ago - GlobeNewsWire

Fennec Pharmaceuticals Inc. (FENC) Q1 2025 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Robert Andrade - Chief Financial Officer Jeff Hackman - Chief Executive Officer...

23 days ago - Seeking Alpha

Earnings Scheduled For May 13, 2025

Companies Reporting Before The Bell • Endeavour Silver (NYSE: EXK) is estimated to report quarterly earnings at $0.03 per share on revenue of $60.52 million. • Intl Game Tech (NYSE: IGT) is expected...

24 days ago - Benzinga

Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025

RESEARCH TRIANGLE PARK, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...

4 weeks ago - GlobeNewsWire

Fennec Pharmaceuticals Inc. (FENC) Q4 2024 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ETCompany ParticipantsRobert Andrade - CFOJeff Hackman -...

3 months ago - Seeking Alpha

Fennec Pharmaceuticals Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

~ Achieved Full-Year PEDMARK ®  Net Product Sales of $29.6 Million, Up 40% Year-Over-Year, and Generated PEDMARK ® Q4 2024 Net Product Sales of $7.9 Million ~

3 months ago - GlobeNewsWire

Earnings Scheduled For March 10, 2025

Companies Reporting Before The Bell • Franco-Nevada (NYSE: FNV) is expected to report quarterly earnings at $0.89 per share on revenue of $305.85 million. • BioNTech (NASDAQ: BNTX) is projected to r...

3 months ago - Benzinga

Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2024 Financial Results on March 10, 2025

RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Com...

3 months ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Commercial Launch of PEDMARQSI® In Germany

~ PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to

4 months ago - GlobeNewsWire

Insider Sell Alert: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC)

Insider Sell Alert: Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (FENC)

4 months ago - GuruFocus

Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

~ PEDMARQSI®  (anhydrous sodium thiosulfate) is the first and only treatment available within NHS England and Wales for the prevention of cisplatin-induced ototoxicity (hearing loss) in children and y...

5 months ago - GlobeNewsWire

Fennec Pharmaceuticals Announces Early Partial Repayment of Its Outstanding Convertible Debt Facility with Petrichor Healthcare Capital Management

~ $13 Million Convertible Debt Repayment from Available Cash ~ ~ Elimination of Approximately $1.5 Million in Annual Interest Expense and Potential Equity Overhang of Approximately 1.6 Million Shares ...

6 months ago - GlobeNewsWire

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...

6 months ago - GlobeNewsWire

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Compa...

7 months ago - GlobeNewsWire

Fennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call Transcript

Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Conference Call November 9, 2024 8:30 AM ETCompany ParticipantsRobert Andrade - Chief Financial...

7 months ago - Seeking Alpha

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to ...

7 months ago - GlobeNewsWire

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...

7 months ago - GlobeNewsWire

Fennec Pharmaceuticals Strengthens Executive Leadership Team with Three Key Appointments to Accelerate the Company's Next Stage of Growth

~ Pierre S. Sayad, PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi, MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, ...

7 months ago - Benzinga

Fennec: Operational Challenges Persist Despite Improved Financial Position

Fennec Pharmaceuticals faces challenges in marketing Pedmark but sees financial boost from Norgine partnership. Read why I recommend holding FENC stock for now.

8 months ago - Seeking Alpha

Insider Sale: Director Rosty Raykov Sells Shares of Fennec Pharmaceuticals Inc (FENC)

Insider Sale: Director Rosty Raykov Sells Shares of Fennec Pharmaceuticals Inc (FENC)

8 months ago - GuruFocus

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Comp...

9 months ago - GlobeNewsWire